Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.67 USD
+0.11 (20.00%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $0.64 -0.03 (-4.76%) 7:22 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SGMO 0.67 +0.11(20.00%)
Will SGMO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGMO
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Other News for SGMO
Peering Into Sangamo Therapeutics's Recent Short Interest
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Buy Rating Affirmed: Sangamo’s Hemophilia A Gene Therapy Poised for Success with Pfizer Partnership
Sangamo reports on Pfizer's Phase 3 results of Hemophilia A candidate